Prime Medicine Inc.

NASDAQ: PRME · Real-Time Price · USD
1.19
0.01 (0.85%)
At close: Jun 02, 2025, 3:59 PM
1.19
0.20%
After-hours: Jun 02, 2025, 07:34 PM EDT

Prime Medicine Statistics

Share Statistics

Prime Medicine has 131.29M shares outstanding. The number of shares has increased by 9.27% in one year.

Shares Outstanding 131.29M
Shares Change (YoY) 9.27%
Shares Change (QoQ) 0%
Owned by Institutions (%) 52.96%
Shares Floating n/a
Failed to Deliver (FTD) Shares 1,505
FTD / Avg. Volume 0.08%

Short Selling Information

The latest short interest is 17.7M, so 13.48% of the outstanding shares have been sold short.

Short Interest 17.7M
Short % of Shares Out 13.48%
Short % of Float 26.11%
Short Ratio (days to cover) 12.73

Valuation Ratios

The PE ratio is -1.77 and the forward PE ratio is -1.18. Prime Medicine's PEG ratio is 0.07.

PE Ratio -1.77
Forward PE -1.18
PS Ratio 116.1
Forward PS 4.8
PB Ratio 2.26
P/FCF Ratio -2.66
PEG Ratio 0.07
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Prime Medicine.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 5.58, with a Debt / Equity ratio of 0.27.

Current Ratio 5.58
Quick Ratio 5.58
Debt / Equity 0.27
Debt / EBITDA -0.21
Debt / FCF -0.31
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $13,939.25
Profits Per Employee $-915,336.45
Employee Count 214
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -81.83% in the last 52 weeks. The beta is 1.9, so Prime Medicine's price volatility has been higher than the market average.

Beta 1.9
52-Week Price Change -81.83%
50-Day Moving Average 1.49
200-Day Moving Average 2.85
Relative Strength Index (RSI) 41.34
Average Volume (20 Days) 1,864,604

Income Statement

In the last 12 months, Prime Medicine had revenue of 2.98M and earned -195.88M in profits. Earnings per share was -1.65.

Revenue 2.98M
Gross Profit -3.15M
Operating Income -202.47M
Net Income -195.88M
EBITDA -196.34M
EBIT -202.47M
Earnings Per Share (EPS) -1.65
Full Income Statement

Balance Sheet

The company has 182.48M in cash and 40.79M in debt, giving a net cash position of 141.68M.

Cash & Cash Equivalents 182.48M
Total Debt 40.79M
Net Cash 141.68M
Retained Earnings -687.21M
Total Assets 328.16M
Working Capital 129.48M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -122.86M and capital expenditures -7.29M, giving a free cash flow of -130.16M.

Operating Cash Flow -122.86M
Capital Expenditures -7.29M
Free Cash Flow -130.16M
FCF Per Share -1.1
Full Cash Flow Statement

Margins

Gross margin is -105.43%, with operating and profit margins of -6787.36% and -6566.61%.

Gross Margin -105.43%
Operating Margin -6787.36%
Pretax Margin -6566.61%
Profit Margin -6566.61%
EBITDA Margin -6581.93%
EBIT Margin -6787.36%
FCF Margin -4363.36%

Dividends & Yields

PRME does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for PRME is $10, which is 740.3% higher than the current price. The consensus rating is "Hold".

Price Target $10
Price Target Difference 740.3%
Analyst Consensus Hold
Analyst Count 7
Stock Forecasts

Scores

Altman Z-Score -4.15
Piotroski F-Score 3